AbbVie (ABBV) announced that the FDA has approved a supplemental new drug application for the combination regimen of venclexta and acalabrutinib for the treatment of previously untreated adult patients with chronic lymphocytic leukemia. The approval is supported by data from the Phase 3 AMPLIFY trial.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- AbbVie initiated with an Overweight at Barclays
- AbbVie’s ABBV-547 First‑in‑Human Trial: What Early Pipeline Moves Mean for ABBV Investors
- AbbVie’s VOLITE Skin Quality Trial Completion: What It Means for ABBV Investors
- AbbVie price target raised to $299 from $289 at Piper Sandler
- AbbVie Advances New Toxin-Based Therapy in Ventral Hernia Trial: What Investors Should Watch